Atea Pharmaceuticals, Inc.

AVIR

$5.81

-0.17%

2026-09-04 12:11:08 EDT-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead ...

Price Action of AVIR

$5.81

-0.17%-$0.01

High—

Low—

52W High-9.9%

Rel. vol—

Interval

Range2.6h

Volume—SMA5SMA10

—

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to addressing unmet medical needs in viral diseases through innovative oral antiviral therapeutics. The company's lead product candidate is a regimen combining bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, currently in Phase 3 clinical ...Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to addressing unmet medical needs in viral diseases through innovative oral antiviral therapeutics. The company's lead product candidate is a regimen combining bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, currently in Phase 3 clinical trials for the treatment of hepatitis C virus (HCV). In addition, Atea is developing AT-587 for chronic HEV infection, currently in Phase 1 trials. The company also has a proprietary platform for nucleosides and nucleotides for virology and antiviral drug development. Atea has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Founded in 2012, the company went public in October 2020 and is listed on NASDAQ under the ticker AVIR. As of the latest data, Atea has approximately 55 full-time employees and operates with a focus on research and development, with no current revenue from product sales. The company's financials show significant investment in R&D and operating losses typical of clinical-stage biopharmaceuticals. Key leadership includes founder and CEO Jean-Pierre Sommadossi, who brings over 30 years of experience in antiviral drug development. Atea's mission is to develop best-in-class oral therapies to improve patient outcomes and address global health challenges.ExpandCollapse

Founded

2012

Employees

CEO

Jean-Pierre Sommadossi

Full Name

Atea Pharmaceuticals, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-64.25%

Market Cap

$0.47B

Current Ratio

8.13

WACC

5.79%

ROIC

-82.19%

Contact Information

https://www.ateapharma.com

857 284 8891

225 Franklin Street, Boston, MA 02110

Key Metrics of AVIR

Snapshot

Latest / TTM · 6 periods

Market Cap

$465.99M

ROCE

-89.9%

EV / EBITDA

-2.24x

-24.3% YoY

FCF Yield

-33.0%

+12.4% YoY

Cash Conversion Cycle

-95.8d

Current Ratio

8.13

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of AVIR

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-2.77x

n/a

Debt / Equity

0.00

n/a

Current Ratio

8.13

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of AVIR

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.51 · Revenue $50.45M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.57 · Revenue $6.58M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.99 · Revenue $5.74M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.44 · Revenue $0.00 · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.41 · Revenue $0.00
View filing
May 12, 2026
Q1 FY2026 · Results reported
EPS $-0.57 · Revenue $0.00
View filing
Mar 5, 2026
FY2025 · Annual results
EPS $-1.94 · Revenue $0.00
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.53 · Revenue $0.00
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-0.44 · Revenue $0.00
View filing
May 12, 2025
Q1 FY2025 · Results reported
EPS $-0.40 · Revenue $0.00
View filing

Financial Statements of AVIR

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-158.3M	+6.0%	+27.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-132.0M	+2.6%	+20.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.3%	-18.2%	-23.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	7.82x	-68.5%	+3.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$315.2M	-32.2%	-13.0%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.94 vs -1.73	-12.5%	-0.41 vs -0.51	+18.8%
Revenue Surprise	$0 vs $7.1M	-100.0%	$0 vs $50.4M	-100.0%

Insider Transactions of AVIR

Acquisitions (A)

Since Jun 18, 2026

Disposals (D)

Since Jun 18, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 18, 2026	Lucidi Bruno	director	Common Stock	A	29,600	—
Jun 18, 2026	Lucidi Bruno	director	Stock Option (Right to Buy)	A	37,700	$4.36
Jun 18, 2026	Lucidi Bruno	director	Restricted Stock Units	A	26,700	—
Jun 18, 2026	Lucidi Bruno	director	Restricted Stock Units	D	29,600	—
Jun 18, 2026	BERGER FRANKLIN M	director	Common Stock	A	29,600	—

Earnings Call Transcript of AVIR

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 26 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. I would now like to turn the call over to Jonae R. Barnes, senior vice president of investor relations and corporate communications at Atea Pharmaceuticals. Miss Barnes, please proceed. Jonae R. Barnes: Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals second quarter 26 Financial Results and Business Update Conference Call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website at ir.atayapharma.com. With me from Atea are our chief executive officer and founder, Dr. Jean-Pierre Sommadossi chief development officer, Dr. Janet J. Hammond chief commercial officer, John F. Vavricka chief medical officer, Dr. Arantxa Horga; chief financial officer and executive vice president of legal, Andrea J. Corcoran, who will be available for the Q&A portion of today's call. Before we begin the call and as outlined on Slide 2, I would like to remind you that today's discussion will contain forward looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission. Which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I will now turn the call over to Jean-Pierre. Jean-Pierre Sommadossi: Thank you, Jonae. Good afternoon, everyone, and thank you for joining us. I will begin on Slide 3. The positive top line results from CBEYOND our phase 3 trial evaluating the combination of BAM versus for the treatment of hepatitis C in North America represent a significant milestone for Atea. And for the millions of people living with hepatitis C, who need a shorter simpler path to cure. We were very pleased that CBEYOND met both its primary and secondary endpoints with bemrusasvir demonstrating statistical non inferiority to Epclusa. The current standard of care. Importantly, this was the first successful phase 3 trial in the global head to head HCV program. Achieved in the real world patient population that was polymedicated psychiatrically complex, substance abuse effective, and adverse challenge. These results reinforce the need for best in class profile designed for the broad and complex hepatitis C population clinicians treat today. Arantxa will review in detail the results of the trial. Threefold, our second phase 3 trial. Being conducted outside North America is fully enrolled, with more than 880 patients and we remain on track to report top line results in early Q1 2027. We believe that the c …

Leadership Team of AVIR

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Jean-Pierre Sommadossi	Founder, Chairman, Chief Executive Officer & President	USD 1,125,584	—	1956	Active
Janet J. Hammond	Chief Development Officer	USD 870,794	—	1960	Active
Andrea J. Corcoran	Chief Financial Officer, Executive Vice President of Legal & Secretary	USD 810,818	Female	1962	Active
Maria Arantxa Horga	Chief Medical Officer	USD 747,102	—	1968	Active
John F. Vavricka	Chief Commercial Officer	USD 634,437	Male	1963	Active
Wayne Foster	Executive Vice President of Finance & Chief Accounting Officer	USD 580,463	Male	1969	Active
Jonae R. Barnes	Senior Vice President of Investor Relations & Corporate Communications	—	Female	—	Active
Xiao-Jian Zhou	Executive Vice President of Early Stage Development	—	Male	—	Active
Adel Moussa	Executive Vice President of Chemistry	—	Male	—	Active
Keith Pietropaolo	Executive Vice President of Clinical Sciences & Project Management	—	Male	—	Active

Recent News of AVIR

Seeking Alpha8/12/2026Neutral

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

MarketBeat8/12/2026Neutral

Atea Pharmaceuticals Q2 Earnings Call Highlights

Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.

GlobeNewsWire8/12/2026Neutral

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV

GlobeNewsWire8/5/2026Neutral

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.

GlobeNewsWire7/28/2026Neutral

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments

Historical Employee Count of AVIR

Current

Change

-1.79%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	55	10-K	Mar 5, 2026	View
Dec 31, 2024	56	10-K	Mar 6, 2025	View
Dec 31, 2023	75	10-K	Feb 28, 2024	View
Dec 31, 2022	70	10-K	Feb 28, 2023	View
Dec 31, 2021	59	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Atea Pharmaceuticals, Inc.